2. Academic Validation
  3. Tricaprin Rescues Myocardial Abnormality in a Mouse Model of Triglyceride Deposit Cardiomyovasculopathy

Tricaprin Rescues Myocardial Abnormality in a Mouse Model of Triglyceride Deposit Cardiomyovasculopathy

  • J Oleo Sci. 2018 Aug 1;67(8):983-989. doi: 10.5650/jos.ess18037.
Akira Suzuki 1,  Satoshi Yamaguchi 1,  Ming Li 1,  Yasuhiro Hara 1,  Hideyuki Miyauchi 2,  Yoshihiko Ikeda 3,  Bo Zhang 4,  Masahiro Higashi 5,  Yasuyuki Ikeda 1,  Atsuko Takagi 1,  Hironori Nagasaka 6,  Kunihisa Kobayashi 7,  Yasuhiro Magata 8,  Toshiaki Aoyama 9,  Ken-Ichi Hirano 1
Affiliations

Affiliations

  • 1 Laboratory of Cardiovascular Disease, Novel, Non-Invasive, and Nutritional Therapeutics (CNT), Graduate School of Medicine, Osaka University.
  • 2 Department of Cardiovascular Medicine, Chiba University Graduate School of Medicine.
  • 3 Department of Pathology, National Cerebral and Cardiovascular Center.
  • 4 Department of Biochemistry, Fukuoka University Medical School.
  • 5 Department of Radiology, Osaka National Hospital.
  • 6 Department of Pediatrics, Takarazuka City Hospital.
  • 7 Department of Endocrinology and Diabetes Mellitus, Fukuoka University Chikushi Hospital.
  • 8 Preeminent Medical Photonics Education & Research Center, Hamamatsu University School of Medicine.
  • 9 Daitocacao Co.,LTD.
PMID: 30012901 DOI: 10.5650/jos.ess18037
Abstract

Triglyceride deposit cardiomyovasculopathy (TGCV) is an intractable Cardiovascular Disease for which a specific treatment is urgently required. In TGCV, adipose triglyceride Lipase (ATGL) deficiency results in the abnormal intracellular metabolism of long-chain fatty acid (LCFA) which leads to TG deposition. Medium-chain triglycerides have been used as an important functional food for various human diseases. To address the potential activities of tricaprin, a medium-chain triglyceride, on cardiac dysfunctions of TGCV, we examined the effects of tricaprin diet on ATGL knock out (KO) mice, an animal model for TGCV. Cardiac imaging tests showed that the tricaprin diet reduced TG accumulation, resulting from improvement of LCFA metabolism, and improved left ventricular function in ATGL KO mice compared to that in mice fed the control diet. In conclusion, tricaprin improved myocardial abnormality in the TGCV model, thus, it may be useful for the treatment of patients with TGCV.

Keywords

adipose triglyceride lipase; capric acid; iodine-123-β-methyl iodophenyl-pentadecanoic acid; medium-chain triglyceride; tricaprin; triglyceride deposit cardiomyovasculopathy.

Figures
Products